Edition:
United States

Novavax Inc (NVAX.O)

NVAX.O on Nasdaq

1.02USD
22 May 2017
Change (% chg)

$-0.02 (-1.92%)
Prev Close
$1.04
Open
$1.06
Day's High
$1.07
Day's Low
$1.00
Volume
4,502,455
Avg. Vol
6,549,544
52-wk High
$8.49
52-wk Low
$0.73

NVAX.O

Chart for NVAX.O

About

Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates... (more)

Overall

Beta: 2.04
Market Cap(Mil.): $293.92
Shares Outstanding(Mil.): 282.61
Dividend: --
Yield (%): --

Financials

  NVAX.O Industry Sector
P/E (TTM): -- 142.93 17.37
EPS (TTM): -0.91 -- --
ROI: -59.67 2.34 -5.89
ROE: -315.44 0.22 -5.30

BRIEF-Novavax reports Q1 loss per share $0.16

* Q1 earnings per share view $-0.17 -- Thomson Reuters I/B/E/S

May 08 2017

BRIEF-Novavax reports Q1 loss per share $0.16

* Q1 earnings per share view $-0.17 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

May 08 2017

BRIEF-Novavax reports Q4 loss per share $0.21

* Novavax reports fourth quarter and year-end 2016 financial results

Feb 27 2017

More From Around the Web

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF79.40 --
Merck & Co., Inc. (MRK.N) $64.04 +0.26
Sanofi SA (SASY.PA) €87.75 --
GlaxoSmithKline plc (GSK.L) 1,642.00 --
AstraZeneca plc (AZN.L) 5,130.00 --

Earnings vs. Estimates